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Lipid Disorders in Uremia
Valdete Topçiu-Shufta and Valdete Haxhibeqiri
Abstract
Lipoprotein has important physiologic functions within the human body. 
Many enzymes, enzyme activators, and protein parts, such as apolipoproteins 
and specific hepatic and extrahepatic receptors, are involved in their metabolism. 
Renal failure is associated with an increased risk of cardiovascular disease. One 
of the main mechanisms underlying this increased cardiovascular risk is dyslipid-
emia. Abnormal lipoprotein profiles are generally a combination of abnormalities 
of all fractions. Uremic lipoprotein profile includes increased triglyceride-rich 
lipoproteins, small dense LDL particles, increased lipoprotein (a), and decreased 
HDL. Enhanced oxidative stress and uremic environment can strongly modify 
plasma lipoproteins, changing their interactions with biological functions and 
especially cardiovascular physiology. This profound lipoprotein disorder has led to 
the formulation of an accelerated atherogenesis hypothesis and has been commonly 
linked with their metabolic alteration associated with uremia.
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1. Introduction
Urea cycle is one of the most important pathways in the human body. The con-
tinuous degradation and synthesis of cellular proteins occur in all forms of life. High 
rates of protein degradation occur in tissue undergoing structural rearrangements.
Approximately 75% of liberated amino acids are reutilized. Since the excess 
amino acids are not stored, those not immediately incorporated into new proteins 
are degraded rapidly. The excess nitrogen from amino acids forms urea. As a 
hydrosoluble compound, urea is excreted by the kidney. Uremia is a clinical syn-
drome marked by elevated concentrations of urea in the blood and is associated 
with many metabolic disorders such as acidosis, abnormalities in lipids, mineral 
and homocysteine metabolism, oxidative stress, chronic inflammation, insulin and 
erythropoietin resistance, vitamin D deficiency, and malnutrition. Uremia more 
commonly develops with chronic kidney disease (CKD), but it also may occur with 
acute kidney injury if loss of renal function is rapid. Nearly all body organs and 
systems are affected by the toxicity of uremic compounds retained in the course of 
renal dysfunction. According to the European Uremic Toxin Work Group, uremic 
toxins are defined as accumulated solutes, normally excreted by the kidneys, that 
interact negatively with biological functions [1]. This has shown the need for the 
search for new uremic compounds, combining them into panels of substances 
involved in the pathophysiological processes. As example we can mention uridine 
adenosine, a strong vasoconstrictor, which is considered as a new uremic toxin. It 
has been demonstrated that uremic patients have increased levels of uridine adenos-
ine, which can influence blood pressure, proliferation rate of vascular smooth 
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muscle cells, and vascular calcification [2]. All these effects correlated with vascular 
dysfunctions and development of atherosclerosis. As uremic toxins are considered 
some components, which concentrations are not directly associated with glomeru-
lar filtration, but interacts negatively with vascular physiology. Several acute-phase 
proteins, IL-1, IL-6, IL-12, α2-macroglobulin, fibrinogen, and myeloperoxidase, 
together with endothelium-related proteins, such as vascular cell adhesion molecule 
1, vascular endothelial growth factor 1, and soluble vascular endothelial growth 
factor receptor, increased in CKD and play a crucial role in endothelium dysfunc-
tion promoting the development of atherosclerosis. Renal failure is associated with 
an increased risk of cardiovascular disease [3, 4]. One of the main mechanisms 
underlying this increased cardiovascular risk is dyslipidemia [2]. In uremic environ-
ment lipids are affected by oxidative stress. The end products of lipid peroxidation 
process affect the circulating lipoproteins, lipidic and proteinic, leading to profound 
alterations of their biological properties, changing their interactions with biological 
functions and especially cardiovascular physiology. For this reason, lipoproteins, in 
renal failure, can be also considered as uremic toxins.
In the human body, dietary lipids absorbed from intestine and lipids synthesized 
by the liver and adipose tissue must be transported between the various tissues and 
organs for utilization and storage. Since lipids are insoluble in water, the problem on 
how to transport them in aqueous blood plasma is solved by associating nonpolar 
lipids (triacylglycerol and cholesterol esters) with amphipathic lipids (phospho-
lipids and cholesterol) and proteins, to form water-soluble particle known as 
lipoproteins.
The plasma lipoproteins are classified as chylomicrons and very-low-density 
(VLDL), intermediate-density (IDL), low-density (LDL), and high-density (HDL) 
lipoproteins, according to their ultracentrifugation characteristics. Chylomicrons 
and VLDL serve as vehicles to transport triglycerides to the sites of consumption, 
as myocytes and suprarenal glands or storage in adipocytes. HDL fraction serves 
as a vehicle to transport surplus cholesterol from peripheral tissues to the liver for 
disposal. Many enzymes, enzyme activators, and protein parts, such as apolipopro-
teins and specific hepatic and extrahepatic receptors, are involved in lipoprotein 
metabolism.
Apolipoproteins (Apo), the protein part of lipoproteins, are present in each 
lipoprotein and carry out several roles. They can be part of the structure of lipo-
proteins, serve as an enzyme cofactors or inhibitors, and finally act as ligands for 
interaction with lipoprotein receptor in tissue. Apolipoproteins of HDL are desig-
nated as A (A-I, A-II, A-IV). Apo A-I is an activator of enzyme lecithin-cholesterol 
acyltransferase (LCAT) and serves as a ligand for HDL binding to specific scavenger 
receptor B1 (SR-B1). Apo A-II is an inhibitor of enzyme lipoprotein lipase. The 
main apolipoprotein of LDL and VLDL is Apo B-100, while the chylomicrons 
contain Apo B-48. Apo B-100 acts as ligand of LDL for LDL receptors in the liver 
and extrahepatic tissue. Apo B-48 is part of the structure of chylomicrons. Apo E 
is found in chylomicrons, VLDL, and HDL, and its role is to uptake the remnant of 
chylomicrons by a receptor specific for apolipoprotein E, in the liver. Apo C-I, Apo 
C-II, and Apo C-III are transferable between several different lipoproteins. Apo C-II 
is activator, whereas Apo C-III is an inhibitor for enzyme lipoprotein lipase. The 
Apo C-I is an inhibitor for enzyme cholesteryl ester transfer protein (CETP).
The main enzymes involved in lipoprotein metabolism are lipoprotein lipase 
(EC 3.1.1.34), hepatic lipase (EC 3.1.1.3), lecithin-cholesterol acyltransferase (EC 
2.3.1.43), and acyl-CoA cholesterol acyltransferase (ACAT) (EC 2.3.1.26).
Lipoprotein lipase is located on the walls of blood capillaries of the heart, adi-
pose tissue, spleen, lung, renal medulla, aorta, lactating mammary gland, and dia-
phragm. It is abundantly produced as an inactive enzyme by myocytes, adipocytes, 
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and several other cell types. The inactive enzyme requires sequential glycation 
and cleavage of a 27-amino acid peptide to become functionally active. The role of 
lipoprotein lipase is the hydrolysis of triglyceride-rich lipoproteins, as chylomicrons 
and VLDL. Apo C-II and phospholipids are cofactors for enzyme activity, while Apo 
A-II and Apo C-III act as inhibitors.
Hepatic lipase is bound to the surface of hepatic cells. Hepatic lipase catalyzes 
hydrolysis and removal of the triglyceride content of HDL and chylomicron rem-
nant. Accordingly, hepatic lipase plays a central role in the metabolism of chylomi-
cron remnants and HDL.
LCAT is the enzyme of HDL, which is activated by Apo A-I, the structural 
protein of HDL. The enzyme plays an important role in HDL-mediated cholesterol 
uptake from the extrahepatic tissues and, as such, serves as a main determinant of 
HDL maturation and plasma HDL cholesterol level.
The formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-
coenzyme A catalyzes the enzyme called ACAT. It is a membrane-bound protein 
and, at the single-cell level, serves as a regulator of intracellular cholesterol homeo-
stasis. In addition, ACAT supplies cholesteryl esters for lipoprotein assembly in the 
liver and small intestine.
Cholesteryl ester transfer protein is a hydrophobic glycoprotein that is secreted 
mainly from the liver and circulates in the plasma, bounded mainly to HDL [5]. It 
mediates cholesterol ester transfer from HDL to IDL in exchange for triglycerides. 
CETP promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to pro-
atherogenic Apo B-containing lipoproteins, including VLDL, VLDL remnants, IDL, 
and LDL. In this way CETP transfers lipids from one lipoprotein particle to another 
in a process that results in equilibration of lipids between lipoprotein fractions.
2. Lipoprotein metabolism
2.1 The metabolism of chylomicrons
The exogenous pathway of lipid metabolism begins with chylomicrons. 
Chylomicrons are responsible for the transport of all dietary lipids into the circula-
tion. They are produced within the enterocytes containing triglycerides, cholesterol 
ester, and phospholipids. Apo B-48 is essential for chylomicron formation. The 
nascent chylomicrons, from the small intestine, are released into the circulation via 
the lymphatic system. In the circulation, the nascent chylomicrons acquire Apo E 
and Apo C-II, which are in the surface of HDL. Apo C-II is an activator for enzyme 
lipoprotein lipase. The endothelium binding accommodates interaction of chylo-
microns with the endothelium-bound lipoprotein lipase. Reaction with lipoprotein 
lipase results in the loss of approximately 90% of triglycerides in chylomicrons. 
The majority of fatty acids released diffuse into the adjacent myocytes for energy 
production or into adipocytes for energy storage. After hydrolysis chylomicron 
remnants are subsequently cleared by the liver and other tissues. Uptake is mediated 
by a receptor specific for Apo E. Both the LDL (Apo B-100 and Apo E) receptor and 
LDL receptor-related protein (LRP), specific for Apo E, are believed to take part. 
Chylomicron remnants return the borrowed Apo C- II and Apo E to HDL before 
their uptake by the liver and other tissues (Figure 1).
2.2 The metabolism of VLDL, IDL and LDL
VLDL particles are produced by the liver and are precursor of IDL and 
LDL. VLDL serves as the vehicle for delivery of endogenous lipids, endogenous 
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triglycerol, and cholesterol, to the peripheral tissues. Nascent VLDL is formed 
within the hepatocyte and Apo B-100. Those are triglyceride-rich lipid droplet, 
followed by the addition of Apo E, Apo A-I, and Apo A-II. The triglycerides and 
cholesterol ester used by hepatocytes for incorporation into VLDL are generated 
by the enzymes acyl-CoA diacylglycerol acyltransferase (DGAT; EC 2.3.1.20) and 
ACAT. Apo C-II and Apo E, borrowed from HDL, are important for subsequent 
metabolism of VLDL by lipoprotein lipase and the VLDL receptor. Enzyme lipo-
protein lipase is activated by the apolipoprotein C-II, and this is followed from the 
hydrolysis of VLDL triglycerides by the activated enzyme, leading to release fatty 
acids, which diffuse into the adjacent myocytes or adipocytes for energy production 
or storage. Lipolysis of VLDL results in reduction in their triglyceride content and 
detachment and release of a remnant particle, known as IDL. IDL particles may 
undergo further lipolysis via hepatic triglyceride lipase. Apo E serves as a ligand for 
remnant VLDL or IDL binding to specific receptors in the liver. This leads to the 
extraction of nearly all remaining triglycerides from IDL by the liver and forma-
tion of cholesterol-rich LDL. LDL particles are then removed via LDL (Apo B-100) 
receptor by the liver, as well as extrahepatic tissue (Figure 2).
2.3 The metabolism of HDL
HDL is synthesized and secreted from the liver and intestine. A major func-
tion of HDL is to act as a repository for the Apo C-II and Apo E, for metabolism 
of triglyceride-rich lipoproteins, chylomicrons, and VLDL. Also, the primary 
function of HDL is retrieval and transport of cholesterol from the tissue to the 
liver which is known as reverse cholesterol transport. This cycle is very important 
for cellular cholesterol homeostasis. The principal apolipoprotein constituents of 
HDL are Apo A-I and Apo A-II. As the main structural constituent of HDL, Apo 
A-I is the activator of enzyme LCAT. LCAT system is involved in HDL-mediated 
removal of excess unesterified cholesterol from triglyceride-rich lipoproteins and 
tissues. Apo A-II serves as an activator of hepatic lipase, which plays a central role 
in the removal of HDL triglycerides by the liver. HDL-mediated removal of surplus 
Figure 1. 
Chylomicron metabolism. Chylomicrons, from the small intestine, are released into the circulation by 
apolipoprotein B-48 (B48). Nascent chylomicrons acquire apolipoprotein (Apo) E (green square) and 
C-II (purple circle), which are in the surface of HDL. Apo A-I (white triangle marked with a) is a main 
apolipoprotein of HDL. Apo E and Apo C-II are necessary for activation of lipoprotein lipase and for 
uptakes of remnant chylomicrons by an LDL receptor and LDL receptor-related protein. TG-triglycerides, 
C-cholesterol, P-phospholipids.
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cholesterol from extrahepatic tissues requires attachment of nascent HDL to the 
ATP-binding cassette transporter type I (ABCA1). Binding to ABCA1 appears to 
trigger active transfer of phospholipids to nascent HDL, a step which is neces-
sary for efficient translocation of free cholesterol from adjacent caveolae to the 
surface of HDL. Free cholesterol reaching the surface of HDL moves to the core of 
HDL. In this process nascent discoidal HDL is transformed into spherical HDL 3. 
After being accepted by HDL3, the free cholesterol is then esterified by LCAT to 
Figure 2. 
Very-low-density lipoprotein metabolism. In circulation VLDL are transformed into intermediate-density 
lipoprotein after lipoprotein lipase activation by apolipoprotein C-II. IDL are removed by hepatic LDL 
receptors specific for apolipoprotein B and E. Apo E and Apo C-II are borrowed from high-density lipoprotein. 
A, Apolipoprotein a; B-100, Apolipoprotein B-100; C, Apolipoprotein C; E, Apolipoprotein E; LDL, low-
density lipoproteins; TG, triglycerides; C, cholesterol; P, phospholipids.
Figure 3. 
High-density lipoprotein metabolism. As the main structural constituent of HDL, apolipoprotein A-I (Apo A-I), 
is the activator of enzyme lecithin-cholesterol acyltransferase. LCAT system is involved in HDL-mediated removal 
of excess unesterified cholesterol from tissues and its esterification. Scavenger receptor B1,and ATP-binding cassette 
transporter type I.
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cholesterol esters, increasing the size of the particles to form the less dense HDL2. 
In the next step, HDL2, released in circulation, participates in a series of elaborate 
exchanges of apoproteins and lipids with the Apo B-containing lipoproteins such 
as chylomicrons, VLDL, and IDL, before reaching the liver. Actually, HDL in 
circulation receives triglycerides from Apo B-containing lipoproteins in exchange 
for cholesterol esters, a process catalyzed by CETP. Finally, HDL-2, via Apo A-I, 
binds to the scavenger receptor B1, which has been identified as a HDL receptor in 
the liver. The cycle is completed by the reformation of HDL 3, either after selec-
tive delivery of cholesteryl esters to the liver via SR-B1 or by hydrolysis of HDL2 
phospholipids and triglycerides by hepatic lipase. Released, free Apo A-I forms 
preβ-HDL with the minimum amount of phospholipid and cholesterol. Preβ-HDL 
is considered the most potent form of HDL in inducing cholesterol efflux from the 
tissues to form discoidal HDL (Figure 3).
3. Oxidative stress, lipid peroxidation, and lipoprotein modifications
CKD is associated with increased oxidative stress, which promotes covalent 
modifications of lipids and lipoproteins. Oxidative stress is an imbalance in the 
reactive oxygen species (ROS) production and their degradation ratio. ROS include 
various compounds such as superoxide anions, hydroperoxide, and hydroxyl radi-
cal. These compounds are produced under physiologic conditions, during energy 
production in mitochondria by reducing oxygen during aerobic respiration.
But excessive ROS levels may have a harmful effect on tissue function and struc-
ture, because of their interaction with different biomolecules in the human body, 
such as nucleic acids, proteins, and lipids. This interaction results with oxidative 
modifications of these biomolecules.
Under physiologic conditions, the production of ROS is balanced by antioxidant 
mechanisms that protect the cells from oxidative damages. The antioxidant mecha-
nisms include enzymes; superoxide dismutase (SOD, EC 1.15.1.1) which catalyzes 
the dismutation of O2•− into H2O2; and glutathione peroxidase (GPX, EC 1.11.1.9), 
which detoxifies H2O2 and other hydroperoxides. Reduced glutathione (GSH), as 
a non-enzymatic antioxidant, allows the scavenging of OH. The redox reactions 
are catalyzed by glutathione peroxidase. In antioxidant mechanisms also included 
several compounds such as HDL, albumin, tocopherols, ferritin, ceruloplasmin, 
transferrin, ubiquinol, flavonoids, and carotenoids.
HDL is well known for its protective antioxidant properties. Protein paraox-
onase-1 (PON1, EC 3.1.8.1), bound to HDL, exhibited antioxidant effects, against 
lipid peroxidation. Selenium Glutathione-peroxidase 3, also known as glutathione 
peroxidase 3 (GPX3, EC 1.11.1.9), is another antioxidant enzyme, which is associ-
ated with HDL. Besides many functions in the human body, albumins are known 
for the antioxidant function too. In the first place concerning the lipid peroxida-
tion, albumin can scavenge hypochlorous acid, responsible for chlorination of 
proteins mediated by myeloperoxidase, and through its reduced cysteine residue 
can scavenge hydroxyl radicals. One of the physiological functions of albumins 
is the transportation of insoluble components, through the blood plasma. In this 
way, albumins bind the long-chain fatty acids (LCFA), polyunsaturated fatty acids 
(PUFAs), and cholesterol and in the circulation, preventing them from oxidative 
modifications. Albumins bind also the ligands such as copper, iron, α-tocopherol, 
bilirubin, and homocysteine and prevent their antioxidant damages. Tocopherol 
is an important antioxidant in the human body, because of its ability to intercept 
intermediary radicals during the lipid peroxidation process. Most antioxidant 
mechanisms described above are decreased in patients with renal failure, leading to 
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a higher sensitivity to oxidative stress. These patients have low activity and con-
centration of Glutathione, low concentration of HDL, PON-1 and GPX3 enzymes, 
albumins and antioxidant vitamins such as vitamin E, D and C. This decreased 
antioxidant status, enhanced oxidative stress, and affected lipids and proteins lead-
ing to lipoproteins modifications and dysfunction. Lipids are one of the compounds 
mostly attached to oxidative stress. The peroxidation of lipids began with the 
reaction between a free radical with a polyunsaturated fatty acid containing more 
than two double bounds and formation of a lipid radical. In the next reaction, lipid 
radical can create lipid peroxyl radicals (LOO•) in reaction with oxygen, which can 
further react with other lipids forming new lipid radicals and lipid hydroperoxide 
(LOOH). Malondialdehyde (MDA) and 4-OH-2,3 alkenals are the end products 
of lipid hydroperoxide degradation. MDA covalently binds to proteins and nucleic 
acids, interfering with their normal biological functions. Binding to nucleic acids, 
MDA induce mutations and base-pair substitutions [6].
Binding to lysine amino group of protein part of lipoproteins, MDA created 
toxic adducts known as advanced lipoxidation end products (ALEs). In general, 
ALEs exhibit several pro-inflammatory effects and are involved in atherosclerosis 
[7]. These ALEs on Apo B result with oxidative modification of [8]. 4-OH-2,3 
alkenals can also react with proteins, exactly with histidine, cysteine, and lysine 
residues and, create ALEs [9], which generate modified LDL. In this modified form, 
LDL can activate macrophages and increase the upregulation of class A scavenger 
receptors involved in the transformation of LDL into foam cells [10]. Another end 
product of lipid peroxidation is F2α-isoprostanes. Oxidation of arachidonic acid 
by a cyclooxygenase-independent pathway generates F2α-isoprostanes, known 
for atherogenic properties, because of their implication on platelet aggregation 
via Thromboxane A2 receptor, vasoconstrictive effects on smooth muscle cells, 
and endothelial cell proliferation and endothelin-1 secretion [11]. These three end 
products are routinely used for in vivo evaluation of lipid peroxidation level [12].
4. Lipid disorders in chronic uremia
Renal failure is characterized by specific metabolic abnormalities of plasma 
lipoproteins [13]. These abnormalities involve all lipoprotein classes and show 
variations depending on the degree of renal impairment. Uremic lipid profile 
includes increased VLDL, IDL, small dense LDL particles, lipoprotein (a), and 
decreased HDL. Besides the changes in their concentration and structure, as stated 
above, uremic environment can strongly modified circulating lipoproteins leading 
to profound alterations of their biological properties and toxic effects in different 
cells and tissues. This has led to the formulation of an accelerated atherogenesis 
hypothesis and has been commonly linked with the lipid metabolic alteration 
associated with uremia.
4.1 Chylomicrons and VLDL
Hypertriglyceridemia is common a disorder in uremic patients. Several studies 
have shown increased concentration of triglycerides even though serum creatinine 
levels are within normal range [14]. The predominant mechanism responsible for 
increased concentration of triglyceride-rich lipoproteins, including chylomicrons, 
VLDL, and their remains, is delayed catabolism and increased synthesis Apo B-48, 
the essential for chylomicrons metabolism. There are evidences that Apo B-48 levels 
are increased and inversely correlated with glomerular filtration and proteinuria 
[15]. In circulation, triglyceride-rich lipoproteins acquire Apo E and Apo C-II, 
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which are in the surface of HDL. In uremic patients, concentrations of Apo E and 
Apo C-II, which are necessary for activation of lipoprotein lipase and for uptakes 
of remnant chylomicrons and VLDL by a receptor specific for Apo E, are reduced. 
Such defect leads to a reduced release of triglycerides in peripheral tissues and to an 
accumulation of triglycerides. Delayed catabolism of triglyceride-rich lipoproteins 
occurs probably because of a decreased activity of hepatic triglyceride lipase and 
lipoprotein lipase. Moreover, significant evidence showed that enzyme lipoprotein 
lipase is lacking in renal failure [16]. There are evidences that diminished activity of 
enzyme is a consequence of the downregulation of the enzyme gene [17]. There is 
also downregulation of hepatic lipase expression [18].
The presence of lipoprotein lipase inhibitors also contributes to delayed tri-
glyceride-rich lipoprotein catabolism. Apolipoprotein C-II is an activator, whereas 
apolipoprotein C-III is a direct lipoprotein lipase inhibitor. A decrease in apolipo-
protein C-II/ apolipoprotein C-III ratio due to a disproportionate increase in plasma 
apolipoprotein C-III may be the cause of lipoprotein lipase inactivation, which 
further contributes to hypertriglyceridemia [19].
As it is mentioned above, triglyceride-rich lipoproteins, chylomicrons, and 
VLDL,need apolipoprotein C-II and apolipoprotein E for their maturation, which 
are delivered by HDL-2. In uremic patients HDL metabolism is impaired and 
HDL-3 are not maturated into HDL-2 due to a LCAT deficiency [20].
In healthy persons, VLDL and chylomicrons are transformed into IDL and 
chylomicron remnants after lipolysis in peripheral tissue. Chylomicron remnants 
are removed by the specific receptors of the liver, via LDL (Apo B-100 and Apo 
E) receptor and LDL receptor-related protein. It has been demonstrated that LDL 
receptor protein is downregulated in uremic patients [21] which leads to increas-
ing levels of exogenous triglycerides. In physiological conditions, surplus IDL is 
transformed into LDL by the removal of their triglycerides by the hepatic lipase 
and enrichment in cholesteryl esters from HDL-2 by CETP. But the lack of HDL-2 
impedes this process and leads to the accumulation of pro-atherogenic IDL [22]. 
There is a downregulation of hepatic lipase expression [18]; thus hepatic lipase 
deficiency which decreased conversion of IDL to LDL and lack of HDL work in 
concert to rise plasma concentration of IDL. A part of VLDL is removed by VLDL 
receptors, but in chronic uremia, the expression of VLDL receptors in tissues is also 
downregulated [23]. This makes impossible the VLDL binding with VLDL recep-
tors in adipocytes and myocytes and their removal from the circulation (Figure 4). 
Insulin resistance is often associated with chronic uremia and seems to be respon-
sible for a hepatic VLDL overproduction [24]. Secondary hyperparathyroidism, in 
renal failure, may play an additional role in triglyceride-rich lipoprotein catabolism 
impairment.
The predominant mechanism responsible for delayed metabolism of chylomi-
crons and very-low-density lipoproteins is increased synthesis apolipoprotein (Apo 
B-48) and low activity of lipoprotein lipase (LPL). Decrease concentration of high-
density lipoproteins in renal failure results with decreased Apo E and Apo C-II, 
which are necessary for activation of LPL and for uptakes of remnant chylomicrons 
and intermediate-density lipoproteins by a receptor specific for Apo E. Such defect, 
together with the downregulation of LDL receptor protein and hepatic lipase (HL), 
leads to accumulation of chylomicron remnants and IDL, reducing the release of 
fatty acids into peripheral tissues. In physiological conditions, surplus IDL is trans-
formed into LDL by the removal of their triglycerides and enrichment in cholesteryl 
esters from HDL-2 by CETP. But the lack of HDL-2 impedes this process and leads 
to the accumulation of pro-atherogenic IDL. Increased activity of CETP contrib-
uted in reducing HDL concentration. The presence of lipoprotein lipase inhibitor, 
Apo C-III, also contributes to delayed triglyceride-rich lipoprotein metabolism.
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4.2 HDL cholesterol
Uremic patients have decreased HDL in comparison with healthy population 
[25, 26]. Several mechanisms, working in concern, may underlie the reduction in 
HDL levels, which is usually indicative of impaired reverse cholesterol transport. 
Specifically, maturation of HDL is impaired and its composition is altered. Thus, 
uremic patients usually exhibit decreased levels of apolipoproteins A-I and A-II 
(the main protein constituents of HDL), diminished activity of LCAT, the enzyme 
responsible for the esterification of free cholesterol in HDL particles, as well as 
increased activity of CETP that facilitates the transfer of cholesterol esters from 
HDL to triglyceride-rich lipoproteins. One of the mechanisms for impaired HDL 
metabolism in uremia is the increased activity of enzyme ACAT which is respon-
sible for intracellular cholesterol esterification. In physiological conditions, Apo A-I 
and Apo A-II, in the circulation, are loaded with cholesterol and phospholipids to 
form nascent HDL. Then, nascent HDL binds to the ABCA-1 receptor on circulating 
macrophages and activates cholesterol ester hydrolase allowing their loading with 
cholesterol. ACAT limits this reverse efflux of cholesterol from macrophages by 
catalyzing the esterification of intracellular cholesterol. Oxidative modification of 
Apo A-I can limit HDL binding on macrophages [27] and upregulation of hepatic 
ACAT [28] contributing in impaired cholesterol efflux. Therefore, an increase in 
ACAT activity can potentially limit HDL-mediated cholesterol uptake and con-
tribute to the reduction in plasma HDL cholesterol and impaired maturation of 
HDL. Although the effect of chronic renal failure on ACAT expression and activity 
in the extrahepatic tissues is not known, chronic renal failure has been recently 
shown to markedly raise hepatic ACAT-2 mRNA and protein abundance, as well as 
total ACAT activity [29].
On the other hand, the activity of enzyme LCAT is decreased [30, 31]. Apo A-I 
is the activator of LCAT, the essential enzyme for the HDL-mediated cholesterol 
retrieval from extrahepatic tissues and as well as ligand for the SR-B1 and HDL-
binding protein (ABCA1 transporter). Apo A-II serves as an activator of hepatic 
lipase, which plays a central role in the removal of HDL triglycerides by the liver. 
As mentioned above, in patients with impaired kidney function, Apo A-I and Apo 
A-II levels are decreased. This reduction contributes to diminished HDL concentra-
tion and impaired HDL maturation. Until recently, it was not clear whether the 
reported reduction in plasma LCAT activity is caused by the reduction in its hepatic 
production and plasma concentration or is a consequence of its inhibition by an 
Figure 4. 
Changes in chylomicrons and VLDL metabolism in renal failure.
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unknown uremic toxin [32]. Another enzyme with diminished activity is CETP. The 
enzyme mediates transfer of cholesterol ester from HDL to IDL in exchange for 
triglycerides. Increased activity of CETP in uremic patients facilitates the transfer 
of cholesterol esters from HDL to triglyceride-rich lipoproteins, reducing the HDL 
cholesterol ester and elevation of HDL triglycerides. The mechanism responsible for 
the elevation of CETP is unknown, but some investigation connected its increased 
synthesis with proteinuria. Probably the same mechanism is responsible for the 
dysregulation of hepatic SR-B1. Hepatic SR-B1 is the primary pathway for the 
disposal of HDL-borne cholesterol ester and triglycerides, and dysregulation of this 
protein can impact HDL metabolism. Heavy glomerular proteinuria has been shown 
to significantly reduce hepatic SR-B1 protein expression in experimental animals 
[29]. HDL has a protective effect against inflammation, platelet adhesion, and LDL 
oxidation. Those protective functions of HDL can be attributed to HDL-associated 
enzymes on its surface. Paraoxonase-1 is considered as the main antioxidant 
enzyme bound to HDL. Mainly expressed in the liver and the kidney, this enzyme 
exhibited antioxidant properties against lipid peroxidation as it binds to HDL and 
in a minor part to VLDL [33]. Glutathione seleno-peroxidase 3, also known as 
glutathione peroxidase 3, is another antioxidant enzyme associated with HDL [34].
One of main anti-atherogenic properties of HDL is a reverse cholesterol trans-
port from circulating macrophages. HDL also increases the production of nitric 
oxide (NO), through the activation of the endothelial NO synthase in endothelial 
cells resulting in a vasorelaxant phenotype. In CKD the production of NO by endo-
thelial cells is significantly reduced with HDL [28]. HDL also inhibits the expres-
sion of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) 
and vascular adhesion molecule-1 (VCAM-1), which prevent the attachment of 
circulating monocytes to endothelial cells. In uremic patients, HDL promotes 
an enhanced expression of VCAM-1 and ICAM-1 on endothelial cells [35, 36]. 
Moreover, CKD-HDL upregulates the expression of pro-inflammatory mediators 
such as monocyte chemoattractant protein-1 (MCP-1), interleukin-1ß (IL-1ß), 
and tumor necrosis factor α (TNF-α) [36, 37]. And finally normal HDL exhibit 
anti-apoptotic effects on endothelial cells through the downregulation of caspase-3 
(a member of the cysteine-aspartic acid protease) activity [38]. All these dimin-
ished protective functions of HDL can contribute to accelerated atherogenesis 
[39]. HDL is very sensitive in oxidative stress and posttranslational modifications. 
Renal failure is associated with an enhanced activity of enzyme myeloperoxidase 
(MPO, EC 1.11.2.2) that plays a crucial role in the generation of posttranslational 
modification derived products (PTMDPs). MPO catalyzed the oxidative reactions 
and formation of a variety of chlorinated protein and lipid adducts. MPO-modified 
ApoA-1 results in decreased reverse cholesterol efflux and a reduced binding with 
ABCA-1 receptor, which disturbed cholesterol homeostasis (Figure 5). 3-chloroty-
rosine, an oxidation product of MPO, impairs the activity of enzymes, LCAT, and 
PON-1, resulting with decreased anti-inflammatory effects of HDL. And through 
the activation of SR-B1 in macrophages, MPO-modified HDL directly contributes 
in atherosclerosis (Figure 5).
In renal failure, decreased activity of lecithin-cholesterol acyltransferase 
impaired the transformation of nascent cholesterol into HDL3 and then into HDL2. 
Increased activity of cholesteryl ester transfer protein facilitates the transfer of 
cholesterol esters from HDL to triglyceride-rich lipoproteins, reducing HDL con-
centration. Removal of free cholesterol from macrophages proceeds by scavenger 
receptor 1. Nascent HDL is generated when Apo A-I interacts with ATP-binding 
cassette transporter type 1 (ABCA1). Than nascent HDL activates cholesterol ester 
hydrolase allowing their loading with cholesterol. ACAT limits this reverse efflux 
of cholesterol from macrophages by catalyzing the esterification of intracellular 
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cholesterol. Increased activity of ACAT, in renal failure, participates in impaired 
cholesterol efflux. Antioxidative and anti-inflammatory functions of HDL are 
impaired due to reduced activity of HDL enzyme PON1. HDL from patients with 
renal failure loses its vasoprotective properties, inhibiting nitric oxide produc-
tion. Oxidative modification of Apo A-I decreases HDLs binding to macrophages. 
Myeloperoxidase-modified Apo A-I decrease reverse cholesterol efflux, reduce 
binding with ABCA1, and impair HDLs anti-apoptotic properties.
4.3 LDL cholesterol
Beyond atherogenic risk of LDL level itself, renal failure leads to various struc-
tural modifications of LDL particles. The lipoproteins found in uremic patients 
are disproportionately modified, with LDL that is enriched in triglycerides. These 
modified LDL particles tend to be smaller and denser in their form. Small dense 
LDL is believed to be markedly pro-atherogenic, and this is attributed to its ability 
to infiltrate the vessel wall and its increased susceptibility to oxidative modifica-
tion. Because of the significantly modified lipid subfraction turnover, residence 
time of lipoproteins in the circulation is prolonged. Thus, lipoproteins are at risk 
of posttranslational modification. LDL receptor-mediated cholesterol uptake plays 
an important role in cholesterol homeostasis. Modified LDL have reduced affin-
ity for the classic LDL receptors and are taken up by the scavenger receptors on 
the surface of the macrophages. These receptors are increased in chronic uremia. 
High affinity for macrophages results in the accumulation of cholesterol and the 
formation of foam cells in the vascular walls, resulting in the development of 
atherosclerotic plaques [40, 41]. Heavy proteinuria alone or in combination with 
chronic uremic state results in acquired LDL receptor deficiency and plays a central 
role in the genesis of the atherosclerosis and cardiovascular diseases. Several levels 
of LDL oxidation can coexist in the bloodstream and lead to the activation of 
several pathways involved in atherosclerosis through their binding to scavenger 
receptors [42] and smooth muscle cell proliferation. There is an evidence that 
OxLDL are accumulated in uremic patients and are correlated with the intensity of 
peripheral arterial disease [43]. Oxidized epitopes of LDL can activate immunity 
and then lead to the formation of antibodies directed against OxLDL. OxLDL/
antibodies against OxLDL ratio were also correlated with carotid atherosclerosis 
Figure 5. 
HDL metabolism in renal failure.
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and cardiovascular events [44]. Formation of OxLDL is a consequence of oxida-
tive stress. As mentioned above, the breakdown of polyunsaturated fatty acids 
produces highly reactive molecules, such as MDA and 4-OH-2,3 alkenals. MDA and 
4-OH-2,3 alkenals can form Schiff bases and covalent Michael-type adducts, with 
lysine residues of Apo B-100, in LDL (Figure 6). The oxidized fatty acid fragments 
which can remain attached via ester bridges, may also contain terminal reactive 
phospholipids which may form adducts with Schiff base lysine residues of Apo 
B-100. Similarly with HDL modifications, increased levels of MPO are involved 
in LDL modifications. MPO can modify LDL through several mechanisms. MPO 
initiated the reaction between hypochlorous acid and tyrosine residues of Apo 
B-100, protein part of LDL, resulting with 3-chlorotyrosine formation, which is 
known for pro-atherogenic properties through its binding with lectin-like oxidized 
LDL receptor 1. MPO also generated reactive nitrogen species, converting LDL into 
a nitrosilated-LDL form. This reaction resulted in nitration of Apo B-100 tyrosyl 
residues of LDL. Carbamylated LDL (cLDL) is another modified form of LDL, 
initiated by MPO. In this reaction MPO catalyzed the addition of thiocyanate, 
derived from the decomposition of urea to the lysine residues of LDL, and leads to 
the formation of carbamylated LDL [45, 46]. The carbamylation occurs by spon-
taneous, nonenzymatic chemical modification of Apo B-100, by thiocyanate. It is 
a irreversibly reaction of thiocyanate with free amino groups and ε-NH2 of lysine 
residues in protein part of LDL (Figure 7). cLDL have pro-atherogenic effects such 
as the transformation of macrophages into foam cells [47] through their binding to 
the pro-atherogenic CD36 receptor [48, 49]. cLDL are associated with endothelial 
toxicity [50, 51] through lectin-like oxidized LDL receptor 1 [52] (Figure 8). cLDL 
levels are raised by chronic uremia [53, 54].
Modified forms of LDL; carbamylated LDL and oxidized LDL; activated 
lectin-like oxidized LDL receptor 1, on endothelial cells; and initiated formation of 
macrophages and smooth muscle cell proliferation.
Figure 6. 
Formation of oxidized LDL.
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4.4 Lipoprotein (a)
The contribution of cardiovascular events to the extraordinary high mortality in 
CKD has generated some interest in nontraditional atherosclerotic cardiovascular 
disease risk factors, which are prevalent in this population, such as Lipoprotein (a) 
[Lp (a)]. Lp (a) is an LDL-like lipoprotein containing a unique apolipoprotein called 
Apo(a). Serum levels of Lp(a) are determined largely by genetic variation in the gene 
encoding for Apo(a). Apo(a) is very homologous to plasminogen [55] and exhibits 
an extreme size polymorphism with the Apo(a) isoproteins, ranging in size from 420 
to 840 kDa. Inherited in an autosomal codominant fashion, the Apo(a) isoprotein 
is closely correlated with serum Lp(a) concentrations, with an inverse correlation 
between the size of the Apo(a) isoprotein and the serum Lp(a) concentrations. Lp(a) 
has been implicated in the regulation of plasminogen activator inhibitor-1 expres-
sion in endothelial cells and shown to inhibit endothelial cell surface fibrinolysis to 
Figure 7. 
Formation of carbamylated LDL.
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attenuate plasminogen binding to platelets and to bind to plaque matrix components. 
Autopsy studies in humans have documented the presence of Lp(a) in aortic and 
coronary atherosclerotic plaques and an apparent colocalization with fibrinogen [56]. 
Lp(a) levels are frequently elevated in uremic patients with CKD [57] and have been 
associated with a frequency distribution of apolipoprotein (a)-Lp(a) isoforms, similar 
to those found in general population. This indicates that elevated Lp(a) levels in these 
patients are not due to the genetic origin [58]. It has been suggested that kidneys have 
an important role in Lp(a) metabolism [59]. In CKD, Lp(a) occurs at high concentra-
tions, largely because of reduced clearance or as a result of increased hepatic synthe-
sis, induced by an acute-phase reaction or by protein losses from proteinuria [60]. 
Uremia can be considered to be a state of activated acute-phase response, and in the 
micro-inflammatory milieu, a number of atherogenic proteins like Lp(a) are acting as 
an acute-phase reactant. Based in all these properties, Lp(a) is a prototype candidate 
to be classified as a uremic toxin.
5. Conclusion
Chronic uremia causes profound alteration in lipoprotein metabolism, promot-
ing the development of atherosclerosis and cardiovascular disease. Besides the 
changes in their concentration, enhanced oxidative stress and uremic environment 
can strongly modify circulating lipoproteins leading to profound alterations of their 
biological properties and can be considered as uremic toxins. Uremic lipoprotein 
profile is directly involve in glomerular capillary endothelial damage and in the 
progression of renal disease. This “reverse epidemiology” shows the importance of 
lipid control to prevent the progression of renal failure.
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